ImmunityBio Inc【IBRX】株式ニュース

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Marketing authorization application for BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in situ (CIS) submitted to...

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding...

Form 4 - Statement of changes in beneficial ownership of securities

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other...

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment PR Newswire FREMONT...

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the...

Form 8-K - Current report

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

High responder rate associated with a duration of response ranging as long as 54 months in QUILT-3.032 with 100 patients enrolled Updated data...

Bourbon_on_my_cornflakes 5日前

Things sure change fast with this stock.
FDA posting is BIG

👍️0

tw0122 5日前

Liking it zone up next $3.23 to $3.70 some being hit now.
$3.22 +'5%

👍️ 1

westjtter 5日前

Well that was a pretty great day up 27%....is this the beginning of the runnup or just a short term pump? Regardless, whether the share price does back off or not, still believe longer term...even just year end, this is going to be a lot higher.

And of course, if Anktiva worldwide approvals continue, revenue starts ramping up, and trials continue to throw off strong data.....well then the share price does have a long way to run....we will see!

👍️ 1

glenn1919 6日前

IBRX....................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783

👍️0

westjtter 7日前

I agree...typically the underwriters support the stock for at least a short period of time(1 to 2 months anyway) so that the offering looks OK to their customers....this one is very strange as the stock has just kept falling...which really does not make a lot of sense if you look at where it was trading before the offering and the price target from their analysts???

I am considering this an anomaly, and have continued to buy and build a position......am I missing something???

👍️0

Bourbon_on_my_cornflakes 7日前

People who bought the december offering at $3 a share sure are tasting some pain. Surprise the underwriters arent supporting the stock better.

👍️0

Bourbon_on_my_cornflakes 7日前

ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price
I wonder if the underwriters exercised this option or not. $3 share price doesnt look to great a deal at the moment.

👍️0

westjtter 2週前

Yes, I believe that management has a plan and this is the first of a slew of positive news coming in 2025....and the bet is that this may be their final equity raise....or at least their final equity raise in the lower single digits....next one(if required) could be in the teens?

I think buying under $3 is as close as you can get to a slam dunk....at the very least, you will see this stock jump up to the mid $3's which will allow a quick profit on a trade....I happen to think that while the share price may be somewhat volatile, we are going a lot higher in 2025.....As for the $30 price target by one of the analysts covering the stock....while that would obviously be a huge upside surprise....I am thinking that upper single digits in 2025 would be a more reasonable guesstimate of where this stock price may be going.

So you can buy for the trade, or you can buy for a longer hold and a decent shot at a huge upside on the share price...IMO of course!!!

👍️ 1

Bourbon_on_my_cornflakes 2週前

IBRX today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code assigned by the Centers for Medicare & Medicaid Services (CMS) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) became effective January 1, 2025. The U.S. Food and Drug Administration (FDA) approved ANKTIVA with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

Healthcare providers may now use the permanent J-code, J9028 (Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram), when submitting claims for ANKTIVA. J-codes are unique identifiers used by U.S. government and commercial payers, as well as physicians and their office staff, to streamline the billing and reimbursement process for intravesically administered therapies and certain other treatments.

More evidence of a revenue ramp-up

👍️0

westjtter 3週前

Here is how I see it…anything under $3 is a real bargain……I see the stock going up at least 20% in the coming months…so you could buy this thing just for a trade ! However i believe it is going a lot higher…the fact that PSS only raised $100 mil, indicates that management believes there is a big jump in revenue coming in 2025, and there will be plenty of news to support the stock price! We will see!

👍️ 2 😁 1

Bourbon_on_my_cornflakes 3週前

Should climb over $3 as offering closed at $3
Bankers begin support and tax loss selling ends today
January effect should be good

Anyone know if the $100 million in stock offering(33 mil shares) is now complete? This was originally to close around Dec 12th....also there was an option for an additional 5 million shares to the underwriters for 30 more days after closing.

Just curious as to who were the buyers of this stock? I would hope and think once this offering closes the share price should slowly start to head higher again.

👍️0

Bourbon_on_my_cornflakes 1月前

Sub $2.50 next week?
Year-end selling killing this one...or is it something else?

👍️0

jondoeuk 2月前

This will be interesting, but we know that cancer cells are able to develop multiple mechanisms that enable the evasion of NKs. These mechanisms are likely the reason why NK based therapies show only limited success in clinic trials. Here is just one mechanism (that was recently found) https://www.cell.com/cell/abstract/S0092-8674(24)00355-6

https://x.com/DrPatSoonShiong/status/1861433583186932141

👍️0

jondoeuk 2月前

A new paper on anti-HER2 CAR-NKs (+/- anti-PD-1) https://academic.oup.com/neuro-oncology/article/26/Supplement_8/viii85/7890050

👍️0

Bourbon_on_my_cornflakes 2月前

what do you think is the biggest factor for the recent rise?

👍️0

glenn1919 3月前

IBRX........................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783

IBRX...................................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783

A case report. From it: ''Here, we report the compassionate use treatment of this combination in a patient with recurrent, metastatic pancreatic cancer (mPC) after 3 lines of therapy. Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months. The patient's disease became stable on this regimen, and a transient complete response was observed by ~14 months of therapy. Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written.'' https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyae267/7814737

👍️ 2

aBeezlee 4月前

$2 would be great. We'll see.

👍️0

Bourbon_on_my_cornflakes 4月前

Wait until it hits $2.50

Hold!

👍️0

axelvento 4月前

bouncer$ ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

https://immunitybio.com/immunitybio-presents-positive-long-term-overall-survival-data-in-non-small-cell-lung-cancer-patients-and-announces-registrational-intent-phase-3-trials-with-anktiva-and-checkpoint-immunotherapy/

Bourbon_on_my_cornflakes 5月前

Down and down, is approval for other cancer expected in June dead?

👍️0

Bourbon_on_my_cornflakes 5月前

Why did IBRX tank so badly in mid August?

👍️0

Bourbon_on_my_cornflakes 5月前

IBRX at $4

Wow. Where is the pancreatic cancer approval expected in June?

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ImmunityBio, Inc. (IBRX)
See https://grabarlaw.com/the-latest/immunitybio-shareholder-investigation/

👍️0

tw0122 7月前

09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.

👍️0

Bourbon_on_my_cornflakes 7月前

Any thoughts on how much revenue FDA approval will bring?

👍️0

wrk_SATX 8月前

Still +54M shares short and time is ticking. 80% inside ownership with a small float.

👍️0

saigai 8月前

up and down.. no problem.. ima staying put

👍️0

saigai 8月前

we know there is a very large short position here.. i think that since the earnings post yesterday and the reaction to it that there is now very little reason to stay short,,lets see that spike

👍️0

carldfw 9月前

Pancreatic Cancer next!!
I like Oncolytics on that list

👍️0

Tahoe2468 9月前

7. ImmunityBio Inc (NASDAQ:IBRX)
Float Shorted: 40.37%

With over 53 million of its shares shorted, ImmunityBio Inc’s (NASDAQ:IBRX) short interest stands at 40.37% as of April 8.

👍️0

jondoeuk 9月前

From Jan 19, 2023: ''ImmunityBio also announced that it held two productive Type B meetings with the FDA in December. The first was to present the recent data and obtain guidance toward a registration pathway in metastatic pancreatic cancer.'' https://www.businesswire.com/news/home/20230119005337/en/ImmunityBio-Announces-Presentation-at-ASCO-GI-2023-of-Fully-Enrolled-Trial-in-Third-Line-and-Greater-Pancreatic-Cancer-and-Update-on-FDA-Type-B-Meetings-Regarding-Paths-to-Registration

What happened?

👍️0

jondoeuk 9月前

Nothing listed in the pipeline.

👍️0

Tahoe2468 9月前

Pancreatic Cancer next!! WOW!!

https://www.prnewswire.com/news-releases/biotechs-role-in-addressing-the-pancreatic-cancer-emergency-302089052.html

👍️0

TrendTrade2016 9月前

IBRX monster bio on the weekly break out

👍️0

MiamiGent 9月前

IBRX Friday Close $7.35+$2.24 (+43.84%)

This morning Pre-Mkt
Bid x Size
$8.13 x 2
Ask x Size
$8.20 x 212
Volume
862,349
90 Day Avg. Vol.
4,851,152

Bona fide squeeze underway. Millions of shares short are trapped.

👍️ 1

carldfw 9月前

Pancreatic will be even better!!In January 2023, ImmunityBio announced that it held two meetings with the FDA in December 2022 to present data and get guidance on a registration pathway for metastatic
pancreatic cancer
. The company's combination immunotherapy
, Nant Cancer Vaccine, has shown potential effectiveness in pancreatic cancer, more than doubling median overall survival (OS) compared to historical OS.

👍️0

martind18 9月前

That’s because IHUB is for pump and dumps.

👍️ 2

Atom Smasher 9月前

Good ole ihub. We have a REAL company here with a remarkable game changing cancer drug whose stock price will not only explode but retain it's stock price and no one here is even talking about it. As per my experience here several years ago.......everyone here is only interested in shells and scam companies. What a shame. That's fine. I'll be making bank. Join me if you want.......or don't. I'm not selling till it's somewhere above 40

👍️ 2

Monksdream 9月前

This a simple bar/volume with 60-minute intervals

The stock is actually trading counter to a recent bearish trend for most tickers according my bit of DD from the Barchart website that would be considered med tech companies
This a link for the sector that is made up 459 tickers
https://www.barchart.com/stocks/quotes/IBRX/competitors?quoteSectors=-MEBI&viewName=main&orderBy=weightedAlpha&orderDir=desc

I have a free membership so I can use the flipcharts function for the past six months of price discovery
One can observe from the sector graph at the top of the page the best time to buy any old med stock was last November
The best time to sell was at the peak last March which isn’t that long ago
I can observe the same recurring pattern in the more than 200 tickers I flipped through

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター